How semaglutide function translates into real weight loss

What the GLP-1 pathway actually does, and why semaglutide exploits it so effectively

GLP-1 (glucagon-like peptide-1) is released by cells in your gut within minutes of eating. Its job is to signal fullness to the brain's hypothalamus, prompt the pancreas to release insulin in response to glucose, and slow the movement of food through the stomach. The problem is that natural GLP-1 is broken down by an enzyme called DPP-4 in roughly two minutes, so its effect is brief.

Semaglutide is a modified version of that hormone, engineered to resist that enzyme. Its half-life stretches to around a week, which is why a single weekly injection (or one tablet taken each morning) keeps GLP-1 receptors activated throughout the whole seven days. Appetite stays lower. Meals feel satisfying sooner. The urge to snack in the evening, which many people describe as their hardest moment, tends to reduce. You can read more about the underlying receptor mechanics on our semaglutide action page.

One practical note: the gut-slowing effect does mean that what you eat alongside semaglutide matters. Fatty or very rich meals can cause more discomfort than they would otherwise, so most prescribers discuss dietary adjustments at the outset. That conversation is part of the clinical review, not an afterthought.

What the trial evidence says about those biological effects in practice

The STEP 1 clinical trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks. Participants taking semaglutide 2.4mg weekly lost an average of around 15% of their body weight. That figure comes from a placebo-controlled setting with lifestyle support alongside the medicine, so the biology and the behaviour worked together, neither alone produces that result.

The newer 7.2mg Wegovy dose, approved by the MHRA in January 2026 and available as a dedicated single-dose pen from April 2026, pushed average weight loss in trials to around 20.7% over 72 weeks. That is approaching the results seen with tirzepatide at its highest dose, which matters if you are comparing options. Our Wegovy overview covers both doses and how the titration schedule works in practice.

These are averages across trial populations. Individual responses vary depending on baseline weight, diet, activity, sleep, and other biological factors. A clinician reviewing your full picture is better placed than any statistic to estimate what is realistic for you. That said, the magnitude of effect seen in semaglutide trials is meaningfully larger than anything achieved with older oral weight-loss medicines.

Where semaglutide's function fits within the UK licensing picture

In the UK, semaglutide for weight management is licensed as Wegovy, the weekly injection and, from 11 June 2026, the once-daily tablet. The NHS medicines page for semaglutide sets out the licensed indications clearly: adults with a BMI of 30 or above, or 27 or above if at least one weight-related condition is present. Lower thresholds apply for some ethnic backgrounds under UK guidance.

Ozempic is also semaglutide, but it carries a different licence (for type 2 diabetes, not weight loss) so it is not the same product for the same purpose, even though the active molecule is identical. Rybelsus tablets are oral semaglutide licensed for diabetes at lower doses (3mg, 7mg, 14mg); the Wegovy weight-loss tablet starts at 1.5mg and escalates to 25mg, a completely different schedule. The distinction matters because the dose and formulation are calibrated to the indication.

For people who are curious about what Wegovy costs privately in the UK, that depends on the dose and provider, our cost page covers the context without the confusion. Worth checking before you assume anything either way.

Side effects, tolerability, and what the function tells us about managing them

Because semaglutide slows gastric emptying and acts on gut receptors directly, the most common side effects are gastrointestinal: nausea, loose stools, constipation, reflux, and occasional vomiting. They are usually most noticeable after starting treatment or after a dose increase, and for most people they ease within a week or two as the body adjusts. Eating smaller portions and avoiding high-fat foods during those first weeks genuinely helps, the biology explains why.

Less common but important: the MHRA's January 2026 Drug Safety Update flagged acute pancreatitis as a known, infrequent but potentially serious risk with GLP-1 medicines. Severe stomach pain that spreads to the back, with or without vomiting, warrants urgent medical attention. Any suspected side effects can be reported at yellowcard.mhra.gov.uk.

Semaglutide is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive, and it is not licensed for under-18s. Certain conditions (including a personal or family history of medullary thyroid carcinoma) require careful prescriber review before starting. Our FAQs page covers some of the most common questions about suitability, and our clinical team reviews every consultation personally before any prescription is issued. One detail people often miss: if you are on oral contraceptives, tirzepatide specifically requires an additional non-oral contraceptive method for the first four weeks and after each dose increase, semaglutide does not carry the same evidence of reduced pill absorption, but it is worth raising with your prescriber.